Olema Pharmaceuticals Inc... (OLMA)
Olema Pharmaceuticals Statistics
Share Statistics
Olema Pharmaceuticals has 68.33M shares outstanding. The number of shares has increased by 22.17% in one year.
| Shares Outstanding | 68.33M |
| Shares Change (YoY) | 22.17% |
| Shares Change (QoQ) | 19.26% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 351 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 6.08M, so 8.9% of the outstanding shares have been sold short.
| Short Interest | 6.08M |
| Short % of Shares Out | 8.9% |
| Short % of Float | 13.81% |
| Short Ratio (days to cover) | 4.93 |
Valuation Ratios
The PE ratio is -2.65 and the forward PE ratio is -2.08. Olema Pharmaceuticals's PEG ratio is -0.94.
| PE Ratio | -2.65 |
| Forward PE | -2.08 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | 0.84 |
| P/FCF Ratio | -3.28 |
| PEG Ratio | -0.94 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Olema Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.5, with a Debt / Equity ratio of 0.
| Current Ratio | 10.5 |
| Quick Ratio | 10.5 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,348,687.5 |
| Employee Count | 96 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -47.37% in the last 52 weeks. The beta is 2.11, so Olema Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 2.11 |
| 52-Week Price Change | -47.37% |
| 50-Day Moving Average | 4.29 |
| 200-Day Moving Average | 8.68 |
| Relative Strength Index (RSI) | 70.98 |
| Average Volume (20 Days) | 947,516 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.26M |
| Net Income | -129.47M |
| EBITDA | -142.26M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.2 |
Balance Sheet
The company has 139.48M in cash and 1.43M in debt, giving a net cash position of 138.05M.
| Cash & Cash Equivalents | 139.48M |
| Total Debt | 1.43M |
| Net Cash | 138.05M |
| Retained Earnings | -435.11M |
| Total Assets | 450.98M |
| Working Capital | 396.71M |
Cash Flow
In the last 12 months, operating cash flow was -104.35M and capital expenditures 0, giving a free cash flow of -104.35M.
| Operating Cash Flow | -104.35M |
| Capital Expenditures | n/a |
| Free Cash Flow | -104.35M |
| FCF Per Share | -1.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OLMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OLMA is $28, which is 428.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 428.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 3.44 |
| Piotroski F-Score | 1 |